Saturday, May 19, 2018

Comparing LogMeIn (LOGM) & Citrix Systems (CTXS)

LogMeIn (NASDAQ: LOGM) and Citrix Systems (NASDAQ:CTXS) are both computer and technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.

Volatility and Risk

Get LogMeIn alerts:

LogMeIn has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Citrix Systems has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

99.2% of LogMeIn shares are owned by institutional investors. Comparatively, 91.5% of Citrix Systems shares are owned by institutional investors. 2.5% of LogMeIn shares are owned by company insiders. Comparatively, 0.6% of Citrix Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares LogMeIn and Citrix Systems’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LogMeIn 13.67% 6.31% 5.03%
Citrix Systems 3.35% 49.52% 12.20%

Dividends

LogMeIn pays an annual dividend of $1.20 per share and has a dividend yield of 1.1%. Citrix Systems does not pay a dividend. LogMeIn pays out 35.8% of its earnings in the form of a dividend.

Earnings and Valuation

This table compares LogMeIn and Citrix Systems’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LogMeIn $989.79 million 5.85 $99.52 million $3.35 33.12
Citrix Systems $2.82 billion 5.07 -$20.71 million $4.14 25.52

LogMeIn has higher earnings, but lower revenue than Citrix Systems. Citrix Systems is trading at a lower price-to-earnings ratio than LogMeIn, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for LogMeIn and Citrix Systems, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LogMeIn 0 1 9 0 2.90
Citrix Systems 2 9 5 1 2.29

LogMeIn presently has a consensus price target of $144.00, suggesting a potential upside of 29.79%. Citrix Systems has a consensus price target of $101.27, suggesting a potential downside of 4.15%. Given LogMeIn’s stronger consensus rating and higher possible upside, equities research analysts plainly believe LogMeIn is more favorable than Citrix Systems.

Summary

LogMeIn beats Citrix Systems on 11 of the 17 factors compared between the two stocks.

About LogMeIn

LogMeIn, Inc., together with its subsidiaries, provides a portfolio of cloud-based communication and collaboration, identity and access, and customer engagement and support solutions for individuals and businesses in the United States, the United Kingdom, and internationally. The company offers GoToMeeting, a secure product for online meetings, sales demonstrations, and collaborative gatherings; GoToTraining, a secure online training product for interactive training sessions; GoToConference, a video and audio conferencing solution; GoToWebinar, a do-it-yourself Webinar product for organizations; join.me, join.me pro, and join.me business, which are online meeting and screen sharing services; OpenVoice, a reservation-less audio conferencing service; and Grasshopper, a provider of telephony solutions. It also provides Bold360 and BoldChat that are live chat and omni-channel engagement services; Bold360 ai, an automated customer service; GoToAssist, GoToAssist Corporate, and GoToAssist Seeit, which offer cloud-based remote support solutions to remotely troubleshoot and fix computers, mobile devices, and apps; LogMeIn Rescue, a remote support and customer care service, which provides remote support through the Internet; LogMeIn Rescue+Mobile and Rescue Lens that are Web-based remote support services. In addition, the company offers LogMeIn Central, a Web-based management console; GoToMyPC that enables mobile workstyles; LogMeIn Pro, a remote access service; and LastPass, a password management and single sign on solution. It serves enterprise customers, small and medium businesses, IT service providers, mobile carriers, customer service centers, OEMs, and consumers. The company was formerly known as 3am Labs, Inc. and changed its name to LogMeIn, Inc. in March 2006. LogMeIn, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

About Citrix Systems

Citrix Systems, Inc. delivers solutions to secure and access applications worldwide. The company offers workspace services, including XenDesktop, a cloud-enabled desktop virtualization solution that gives customers the flexibility to deliver desktops and applications as a service from cloud and on-premises datacenters; and XenApp that allows Windows applications to be delivered as cloud services to Android and iOS mobile devices, Macs, PCs, and thin clients. Its workspace services also comprise XenMobile enterprise mobility management solutions; and Citrix Workspace Suite, which provides apps, desktops, branch networking and WAN, enterprise mobility management, and data solutions. In addition, the company offers networking products comprising NetScaler ADC, a software-defined application delivery controller and load balancer for mobile, remote, and branch users; and NetScaler SD-WAN, an integrated platform that enhances traditional enterprise applications, SaaS applications, and virtual desktops for remote users. Further, it provides content collaboration services that include ShareFile, a cloud-based file sharing and storage solution, which provides enterprise-class data services on various corporate and personal mobile devices for businesses. Additionally, the company offers subscription, software solutions, hardware maintenance, professional consulting, and product training and certification services. It markets and licenses its products through resellers, distributors, systems integrators, independent software vendors, original equipment manufacturers, and service providers. The company was formerly known as Citrus Systems, Inc. Citrix Systems, Inc. was founded in 1989 and is headquartered in Fort Lauderdale, Florida.

Monday, August 3, 2015

Top 5 High Dividend Stocks To Watch Right Now

Top 5 High Dividend Stocks To Watch Right Now: Acceleron Pharma Inc (XLRN)

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company's research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.

The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company's two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to tr! eat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blo od cell disorders are generally unresponsive to approved dru! gs. The Company's third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.

The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and M DS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.

Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.

Advisors' Opinion:
  • [By Ben Levisohn]

    3. We see 23+ partnered pipeline assets and are most po! sitive on! Phase I/II MOR202 anti-CD38 for myeloma with data in 2015, and others such as Acceleron Pharma (XLRN), Agios Pharmaceuticals (AGIO), Epizyme (EPZM), Concert Pharmaceuticals (CNCE) (just started Phase I for next-gen Revlimid).

  • [By Jake L'Ecuyer]

    Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.74 percent to $39.54 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.

  • [By Jake L'Ecuyer]

    Shares of Acceleron Pharma (NASDAQ: XLRN) got a boost, shooting up 16.39 percent to $39.42 after Form 8-K for Acceleron Pharma showed that Celgene (NASDAQ: CELG) will buy 1.1 million shares for $47.15 million.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-high-dividend-stocks-to-watch-right-now-2.html